On October 10, 2024, Xencor, Inc. announced that preclinical data on XmAb942 was published in a poster. XmAb942 is an investigational high-potency extended half-life anti-TL1A antibody.
The data was presented during United European Gastroenterology (UEG) Week on October 15, 2024, in Vienna, Austria. XmAb942 is being developed for patients with inflammatory bowel diseases.
This presentation highlights the early scientific progress of XmAb942, providing foundational information as the program advances towards clinical studies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.